Volcano, ev3 sign distribution agreement
This article was originally published in The Gray Sheet
Executive Summary
Volcano enters a three-year agreement, under which its 80-rep U.S. sales team will sell ev3's SpiderFX embolic protection device in conjunction with Volcano's intravascular ultrasound and functional measurement devices for use in saphenous vein grafts. Financial details of the arrangement, announced April 3, were not disclosed. ev3, which also makes stents and catheters, will continue to sell SpiderFX for SVG and carotid indications. The same day, ev3 announced first quarter sales of $61.5 million, a 46% increase over the prior-year period...